Email ID
Password
Scrip   
CHMP gives nod to GSK's Revolade
22 December 2009
Katie McQue

The EU's CHMP has supported the approval of GlaxoSmithKline's novel treatment for chronic idiopathic thrombocytopenic purpura (ITP) Revolade (eltrombopag 25mg and 50mg, film-coated tablets) in patients who have had their spleen removed, and who do not respond to other treatments, such as...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36